VWR expands deal with enzymes firm NEB in latest biopharma-focused expansion

By Gareth Macdonald

- Last updated on GMT

Related tags Molecular biology

VWR expands enzymes deal
VWR expands enzymes deal
VWR has expanded its distribution deal with industrial enzymes firm New England Biolabs (NEB) in its latest biopharma-focused move.

The agreement – terms of which were not disclosed – will allow VWR’s biopharmaceutical industry customers to access NEB’s products through its online portal and onsite services group.

NEB spokesman Andrew Bertera said: "The support and reach of VWR's sales team will help showcase our expanding portfolio of innovative products to a larger number of researchers" adding that "we are excited about the expanded access and ease of ordering this will provide to customers.​"

The firm discovers and makes enzymes for molecular biology applications, including recombinant and native enzymes for genomic research, genome editing, synthetic biology and sequencing.

Post IPO biopharma focus

VWR completed its IPO last October and the NEB deal comes a few months after the firm expanded into the single-use technology sector through the acquisition of Integra Companies and STI Components.

Massachusetts-based Integra Companies provides single use connectivity solutions including tubing, hoses and gaskets for high-purity environments for biopharma companies.  Integra is ISO9001 certified and operates two ISO Class 7 clean rooms.

North Carolina-based STI Components offers high-purity fluid handling components and custom engineered solutions in the Southeast US.  

Last month the firm bought National Biochemicals (NBC), a full service raw material manufacturer and supplier to the biochemical industry, citing expansion of its biochemical manufacturing portfolio as the driver for the deal.

At the time CEO Manuel Brocke-Benz said: "We continue to make targeted, strategic investments that give VWR access to the high growth biochemical industry​.” 

Related news

Related product

Follow us


View more